Nagrestipen
Source Nagrestipen at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Nagrestipen is an experimental small‑molecule compound identified in a recent transcriptomic analysis of ischemic stroke as a candidate regulator of the chemokine gene Ccl3. The study suggests that, by influencing Ccl3 expression in basophils and their interaction with neutrophils, nagrestipen might affect the senescence‑associated secretory phenotype (SASP) and downstream immune processes that contribute to stroke pathology in humans and animal models.
Mechanism of Action
The only mechanistic insight reported for nagrestipen comes from a bioinformatic drug‑prediction step in a study of ischemic stroke. The authors forecast that nagrestipen can down‑regulate Ccl3 transcription in basophils, thereby diminishing Ccl3‑mediated apoptotic signalling and altering basophil‑neutrophil crosstalk. Through this putative effect on Ccl3, the compound may modulate the senescence‑associated secretory phenotype and broader immune‑response pathways implicated in stroke progression.
What the Research Shows
Two peer‑reviewed sources mention nagrestipen. A 1998 USAN Council note simply records the assignment of the United States Adopted Name ‘Nagrestipen’ without providing any pharmacological or clinical information. The only substantive investigation appears in a 2025 Frontiers in Neurology article that examined senescence‑associated secretory phenotype (SASP) genes in human blood and a mouse middle‑cerebral‑artery‑occlusion (MCAO) model of ischemic stroke. Using bulk and single‑cell transcriptomics, the authors identified fourteen hub genes, highlighted Ccl3 as a key mediator in basophil‑neutrophil interactions, and employed a drug‑prediction algorithm that suggested nagrestipen could regulate Ccl3 expression. The prediction was not experimentally validated; the study confirmed altered Lcp1 and Ccl3 mRNA levels in the MCAO rat model but did not test nagrestipen itself.
Reported Benefits
If the computational prediction proves accurate, nagrestipen could offer a novel means of attenuating Ccl3‑driven inflammation and apoptosis in the acute phase of ischemic stroke. By modulating the SASP and basophil‑neutrophil communication, the compound might limit infarct expansion and improve neurological outcomes. However, these potential benefits are currently speculative, based solely on in‑silico drug‑target association and have not be demonstrated in cellular, animal, or human experiments.
Limitations of the Evidence
The evidence for nagrestipen is limited to a single bioinformatic prediction within a broader transcriptomic study of stroke. No experimental data demonstrate that the compound binds Ccl3, alters its expression, or influences disease phenotypes. Pharmacokinetic, pharmacodynamic, toxicity, and dosing information are absent, and the USAN listing provides no functional description. Consequently, the therapeutic relevance of nagrestipen remains untested, and its utility cannot be inferred from the current literature.
Safety Considerations
No safety or adverse‑event data for nagrestipen are reported in the available publications. The USAN entry supplies only the name, and the 2025 stroke study does not include any in‑vivo or in‑vitro testing of the compound. Therefore, potential toxicity, organ effects, or contraindications are unknown, and any safety considerations remain entirely speculative until experimental evaluation is performed. Caution is advised in any future preclinical work.
How It Is Administered
The route of administration, formulation, and dosing regimen for nagrestipen have not been described in the literature. The compound’s physicochemical properties and suitability for oral, intravenous, or other delivery methods remain unknown. Consequently, no guidance can be provided on how the drug would be administered in experimental or clinical settings.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleLowXie D, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleLow1998-01-01T00:00:00.000000Z
Frequently Asked Questions
What is nagrestipen?
Nagrestipen is a newly named small‑molecule that appears in a 2025 transcriptomic study of ischemic stroke as a computationally predicted regulator of the immune‑related gene Ccl3. No further pharmacological description is available.
Has nagrestipen been tested in animals or humans?
No experimental testing of nagrestipen has been reported. The cited stroke study measured gene expression changes in a mouse model but did not administer the compound, and the USAN listing provides no clinical data.
What is known about how nagrestipen works?
The only mechanistic claim is a bioinformatic prediction that nagrestipen could down‑regulate Ccl3 transcription in basophils, potentially influencing apoptosis and immune cell communication linked to the senescence‑associated secretory phenotype.
Are there any safety or side‑effect data for nagrestipen?
Safety information is absent from the literature. Neither the USAN entry nor the stroke research article reports toxicity, adverse events, or contraindications, so any safety profile remains entirely unknown.